Eli Lilly agreed to acquire CrossBridge Bio in a deal valued at up to $300 million to expand its oncology pipeline in dual-payload antibody-drug conjugates. CrossBridge’s platform is built to attach two cytotoxic payloads to one antibody, with the goal of improving potency while addressing drug-resistance challenges. CrossBridge’s lead candidate CBB-120 is expected to move toward an IND filing later this year. Lilly framed the move as a continuation of its targeted cancer strategy that increasingly includes ADC capability across earlier lines and resistant tumor settings.